PATENT CLAIM ANALYSIS

Application Number: 15974855
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "021910"]

Abstract:
This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.

Claim (Index 33):
The method of  claim 29 , wherein the pharmaceutical composition is a topical composition.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.40299
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15288863', '09860750', '14747578', '13709610', '12165838']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8098400170613191
- 35 USC 102 Novelty (BERT): 0.5623648174123668
- Combined Prediction Score: 0.7850924970964239
- Mean Citation Score: 397.129816
- Max Citation Score: 543.6747
- Similarity Product: 302.7540797636211

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test